Clinical Trials List
2025-10-09 - 2033-12-31
Phase I/II
Recruiting2
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/01
Investigators and Locations
Co-Principal Investigator
- Shang-Yin Wu Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
- Seu-Chun Yang Division of General Internal Medicine
- Wu-Chou Su Division of Hematology & Oncology
- Po-Lan Su Division of General Internal Medicine
- Chian-Wei Chen Division of General Internal Medicine
- 蔡政軒 Division of General Internal Medicine
- 林建佑 Division of General Internal Medicine
- Chin-Wei Kuo Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 高冠鈞 Division of Hematology & Oncology
- Mei-Chuan Chen Division of Thoracic Medicine
- Shang-Fu Hsu Division of Thoracic Medicine
- Kai-Ling Lee Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
5 participants
-
Global
242 participants
